Abstract
Purpose
Cyst infections are a common complication in autosomal dominant polycystic kidney disease (ADPKD). Diagnosing these infections often remains challenging. Conventional imaging techniques such as ultrasonography, computed tomography (CT), and standard magnetic resonance imaging have several drawbacks and disadvantages. The purpose of this pictorial essay was to illustrate and discuss the potential value of 18F-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET)/CT in diagnosing cyst infection in ADPKD.
Methods
Exemplary (ADPKD) patients who underwent FDG-PET/CT as part of their routine clinical work-up in our institution are presented to show the potential value and drawbacks of this imaging technique in diagnosing cyst infection. In addition, the current literature and guidelines on this topic were reviewed.
Results
FDG-PET/CT appears to be a sensitive method for the detection of cyst infection, but it is not infallible. Furthermore, FDG uptake in cysts and cyst-like lesions is not specific and clinical and radiological correlations are essential to improve specificity and minimize the risk of falsely discarding other diseases, in particular malignancy.
Conclusion
FDG-PET/CT seems to be a useful imaging modality to diagnose cyst infections in ADPKD. However, its exact diagnostic value has not been established yet due to the lack of a reliable reference standard in previous studies on this topic.
Similar content being viewed by others
Explore related subjects
Discover the latest articles, news and stories from top researchers in related subjects.Avoid common mistakes on your manuscript.
Introduction
Autosomal dominant polycystic kidney disease (ADPKD)
ADPKD is the most common hereditary kidney disease that leads to end-stage renal disease [1]. Over the course of years, patients with ADPKD develop multiple cysts in their kidneys. Hepatic cysts are the most common extrarenal manifestation of ADPKD, which can be found in 80% of patients at the age of 30. While ADPKD is often asymptomatic in childhood, progressive expansion of the cysts leads to end-stage renal disease between age 58 and age 80 on average, depending on the causative genetic mutation (PKD1 or PDK2, respectively) [2].
The clinical symptoms of ADPKD are often directly related to the expansion of renal cysts. Patients usually present with complaints of pain, hematuria, but gastrointestinal symptoms such as obstipation and weight loss can also occur [3]. Elevated blood pressure due to increased activity of the renin–angiotensin system is also common [4].
ADPKD is usually diagnosed according to the criteria of Ravine [5], which are based on ultrasonographic imaging and take into account the family history and age of the patient. Patients with a positive family history between the ages of 15 and 29 with more than two renal cysts in total, between 30 and 59 with two cysts in each kidney, or above 60 with more than 4 cysts in each kidney are diagnosed as having ADPKD. Without a positive family history, ADPKD can be diagnosed if more than ten cysts are present in each kidney, regardless of age.
Besides hypertension, end-stage renal disease and pyelonephritis, cyst infection is a common complication of ADPKD [6, 7]. Patients with a cyst infection usually present with symptoms such as flank pain and fever, mostly accompanied by an increased level of C-reactive protein (CRP) and leukocytosis. Because flank pain and fever are also common in cyst hemorrhage, pyelonephritis, and nephrolithiasis, further diagnostic methods are necessary to settle the correct diagnosis [8].
Although cyst infection has a prevalence of up to one in two patients with ADPKD, diagnosis remains challenging [9]. The diagnostic reference is analysis of the cyst fluid, but cyst punctures can cause bleeding, rupture, and contamination of adjacent cysts and are therefore rarely performed [10].
The purpose of this pictorial essay was to illustrate and discuss the potential value of FDG-PET/CT compared to conventional imaging methods (ultrasonography, CT, and MRI) in diagnosing cyst infection in ADPKD.
Conventional imaging
Ultrasonography is often the initial step in locating the source of lower abdominal pain that is common in patients with cyst infections. It is relatively cheap compared to other cross-sectional imaging methods, does not use any potentially harmful ionizing radiation, and also allows exclusion of hydronephrosis.
However, ultrasonography and other conventional radiologic modalities such as CT and standard magnetic resonance imaging (MRI) are often of limited use in diagnosing infection [11,12,13]. A diagnosis of infection with these modalities is mostly based on wall thickening and heterogeneous content of the cysts. However, since the presence and expansion of numerous cysts in polycystic disease often severely affects the normal anatomy of the affected organ, wall thickening can reflect residual functional parenchyma, and harmless intracystic cellular debris can also cause a heterogeneous cyst appearance. As a consequence, it is hard to distinguish between infected and non-infected cysts [13].
Besides these limitations, iodinated CT contrast agents and gadolinium-based MRI contrast agents can be contraindicated in patients with impaired renal function (due to ADPKD) because of the potential risks of nephrotoxicity and nephrogenic systemic fibrosis, respectively [13]. Of interest, diffusion-weighted MRI is a relatively new MRI technique that is sensitive to the random (Brownian) motion of water molecules, and can provide a high lesion-to-background contrast. Although it is particularly used in oncology, it may also be used to diagnose (cyst) infections. A recent study showed a sensitivity and specificity around 80% for diagnosing cyst infection with combined MRI findings, which included high intracystic signal intensity on diffusion-weighted imaging MRI and wall thickening. However, only patients with severe cyst infection were included, and the specificity dropped to 66% when patients had organomegaly, which is common in ADPKD [14]. Therefore, there is a need for alternative imaging methods for the evaluation of these patients.
FDG-PET/CT
18F-fluoro-2-deoxy-d-glucose (FDG) positron emission tomography (PET) is considered a potentially useful imaging technique for detecting cyst infection. Activated inflammatory and infectious cells (such as macrophages, lymphocytes and neutrophils) require a high amount of glucose and therefore also accumulate FDG [15]. The FDG accumulation can be visualized by PET with a high contrast-to-background ratio, and the concomitantly acquired low-dose CT can be used to anatomically pinpoint the sites of FDG accumulation and therefore sites of potential infection.
Various recent studies have investigated the diagnostic value of FDG-PET/CT in diagnosing cyst infections. For example, Sallée et al. [16] described 8 patients in whom a cyst infection was diagnosed based on FDG-PET/CT. Five patients had a definite cyst infection based on cyst aspiration, and three patients a probable cyst infection based on the presence of all of the following five factors: fever, abdominal pain, increased CRP, the absence of cyst bleeding and the absence of any other possible cause of fever. In all 8 patients, FDG-PET/CT results were positive for infection (Figs. 1, 2, 3, 4 and 5).
Bobot et al. [10] described 32 cases of clinically suspected cyst infections in 24 patients where FDG-PET/CT achieved a sensitivity of 77% and a specificity of 100% for diagnosing cyst infection. Three FDG-PET/CT positive cases were regarded as definitive cyst infection based on cyst aspiration, the other 11 FDG-PET/CT positive cases were considered as ‘likely cyst infections’ based on the five criteria of Sallée et al. [16]. Long treatment with antibiotics before the FDG-PET/CT scan was suggested as the most likely explanation for false-negative cases.
Balbo et al. [17] described 32 cases of clinically suspected cyst infections in 27 patients where FDG-PET/CT was reported to have a sensitivity of 95% and a specificity of 100%. Among these, there were 24 episodes of cyst infection in 18 patients. Six cases were definite cyst infections based on cyst aspiration, the other 18 cases were ‘probably cyst infections’, also based on the criteria of Sallée et al. [16].
Finally, we recently analyzed 37 cases in 32 patients where FDG-PET/CT achieved a sensitivity of 86% and a specificity of 81%, with 18 true-positive and 11 true-negative cases (data not published yet). All cases were assessed based on the criteria of Sallée et al. [16], because no cyst punctures were performed.
Discussion
Cyst infections are often a diagnostic challenge, particularly in case of polycystic disease such as ADPKD. We reviewed the current evidence and provided exemplary cases to illustrate the potential benefits and pitfalls of FDG-PET/CT in diagnosing cyst infection.
In cases 1 and 3, the correct diagnosis of a cyst infection was based on a positive FDG-PET/CT scan, and in case 2 a suspected cyst infection was ruled out. In cases 1 and 3, the patients clinically improved on antibiotics able to penetrate cyst walls, and in case 2, the patient improved on a course of nitrofurantoin for cystitis. All patients were discharged from hospital in good clinical condition.
Case 4 illustrated that FDG-PET/CT can also result in a false positive diagnosis of a cyst infection in more complicated cysts. Increased FDG uptake in complicated cyst-like structures is not specific for infection and can also reflect malignancy [18]. This was also shown in case 5, where a complicated cyst (Bosniak category 3–4) did not show markedly increased FDG uptake, although pathologic testing later confirmed the presence of multiple infected cysts.
In the current guidelines for use of FDG-PET/CT in inflammation and infection, several diseases are marked as ‘major indication’ based on sufficient evidence in literature of FDG-PET/CT’s high sensitivity and specificity in these diseases [19]. These include, for example, sarcoidosis, spinal infection, and vasculitides. Other useful applications that are mentioned, but are not a major indication yet due to insufficient evidence, include evaluation of suspected infection of intravascular devices and potentially infected hepatic and renal cysts in polycystic diseases.
These guidelines, however, were established in 2013 based on 7 studies reporting in total only 34 scans in 28 patients [20,21,22,23,24,25,26]. Since then, various larger studies were published, including in total more than a hundred cases and describing in all cases a high sensitivity and specificity for FDG-PET/CT in diagnosing cyst infection ([10, 17], own study (not published yet)). Therefore, it seems appropriate to reassess the guidelines and to state whether a suspected cyst infection in polycystic diseases should be considered a major indication for performing an FDG-PET/CT scan.
However, the main limitation of these recent studies [10, 16, 17] was the lack of a gold diagnostic standard to validate the results of the FDG-PET/CT scan. As mentioned previously, cyst puncture is currently the only true gold diagnostic standard, but it may lead to serious complications and is therefore rarely performed. The majority of the cases that were considered as true positives were diagnosed based on the five clinical criteria from Sallée et al. [16]. Therefore, patients who missed one or more of the clinical criteria from Sallée et al. [16] but did show signs of cyst infection on the FDG-PET/CT scan were considered as false positives. Patients who met all five criteria but did not show signs of infection on the FDG-PET/CT scan, were considered as false negatives. The possibility that at least some patients were suffering from a cyst infection without showing all clinical criteria from Sallée et al. seems plausible [16].
In conclusion, FDG-PET/CT is a potential imaging modality to diagnose cyst infections in ADPKD. However, due to the lack of a solid reference standard, most studies in this field relied on a combination of clinical factors to diagnose cyst infection, which is which is a far from optimal method to validate a new diagnostic tool to validate a new diagnostic tool.
References
Steinman TI (2012) Polycystic kidney disease: a 2011 update. Curr Opin Nephrol Hypertens 21(2):189–194
Chebib FT, Torres VE (2016) Autosomal dominant polycystic kidney disease: core curriculum 2016. Am J Kidney Dis 67(5):792–810
Meijer E, de Jong PE, van der Jagt EJ, Peters DJ, Breuning MH, Gansevoort RT (2009) Erfelijke cystenieren: nieuwe inzichten en mogelijke geneesmiddelen. Ned Tijdschr Geneeskd 153:B101
Barrett BJ, Foley R, Morgan J, Hefferton D, Parfrey P (1994) Differences in hormonal and renal vascular responses between normotensive patients with autosomal dominant polycystic kidney disease and unaffected family members. Kidney Int 46(4):1118–1123
Ravine D, Gibson RN, Walker RG, Sheffield LJ, Kincaid-Smith P, Danks DM (1994) Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. Lancet 343:824–827
Tkachenko O, Helal I, Shchekochikhin D, Schrier RW (2013) Renin–Angiotensin–aldosterone system in autosomal dominant polycystic kidney disease. Curr Hypertens Rev 9(1):12–20
Hateboer N, V dijk MA, Bogdanova N et al (1999) Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1–PKD2 study group. Lancet 353(9147):103–107
Hogan MC, Norby SM (2010) Evaluation and management of pain in autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis 17(3):e1–e16
Alam A, Perrone RD (2009) Managing cyst infections in ADPKD: an old problem looking for new answers. Clin J Am Soc Nephrol 4(7):1154–1155
Bobot M, Ghez C, Gondouin B, Sallée M, Fournier PE, Burtey S, Legris T, Dussol B, Berland Y, Souteyrand P, Tessonnier L, Cammilleri S, Jourde-Chiche N (2016) Diagnostic performance of [(18)F]fluorodeoxyglucose positron emission tomography-computed tomography in cyst infection in patients with autosomal dominant polycystic kidney disease. Clin Microbiol Infect 22(1):71–77
Fick GM, Johnson AM, Hammond WS, Gabow PA (1995) Causes of death in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 5(12):2048–2056
Lantinga MA, Drenth JP, Gevers TJ (2015) Diagnostic criteria in renal and hepatic cyst infection. Nephrol Dial Transplant 30(5):744–751
Jouret F, Lhommel R, Devuyst O, Annet L, Pirson Y, Hassoun Z, Kanaan N (2012) Diagnosis of cyst infection in patients with autosomal dominant polycystic kidney disease: attributes and limitations of the current modalities. Nephrol Dial Transplant 27(10):3746–3751
Suwabe T, Ubara Y, Ueno T et al (2016) Intracystic magnetic resonance imaging in patients with autosomal dominant polycystic kidney disease: features of severe cyst infection in a case–control study. BMC Nephrol 17(1):170
Vaidyanathan S, Patel CN, Scarsbrook AF, Chowdhury FU (2015) FDG PET/CT in infection and inflammation—current and emerging clinical applications. Clin Radiol 70(7):787–800
Sallée M, Rafat C, Zahar JR, Paulmier B, Grünfeld JP, Knebelmann B, Fakhouri F (2009) Cyst infections in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 4(7):1183–1189
Balbo BE, Sapienza MT, Ono CR, Jayanthi SK, Dettoni JB, Castro I, Onuchic LF (2014) Cyst infection in hospital-admitted autosomal dominant polycystic kidney disease patients is predominantly multifocal and associated with kidney and liver volume. Braz J Med Biol Res 47(7):584–593
Oyama N, Ito H, Takahara N et al (2014) Diagnosis of complex renal cystic masses and solid renal lesions using PET imaging: comparison of 11C-acetate and 18F-FDG PET imaging. Clin Nucl Med 39(3):e208–e214
Jamar F, Buscombe J, Chiti A et al (2013) EANM/SNMMI guideline for 18F-FDG use in inflammation and infection. J Nucl Med 54(4):647–658
Sainaresh V, Jain Sh, Patel H, Shah P, Vanikar A, Trivedi H (2011) Post transplant urinary tract infection in autosomal dominant polycystic kidney disease a perpetual diagnostic dilema-18-fluorodeoxyglucose- positron emission computerized tomography—a valuable tool. Indian J Nucl Med 26:109–111
Agrawal K, Bhattacharya A, Singh SK, Manohar K, Kashyap R, Mittal BR (2011) Polycystic kidney disease: renal cyst infection detected on F-18 FDG PET/CT. Clin Nucl Med 36:1122–1123
Piccoli GB, Arena V, Consiglio V et al (2011) Positron emission tomography in the diagnostic pathway for intracystic infection in adpkd and “cystic” kidneys: a case series. BMC Nephrol 12:48
Jouret F, Lhommel R, Beguin C et al (2011) Positron-emission computed tomography in cyst infection diagnosis in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 6:1644–1650
Jiménez-Bonilla JF, Quirce R, Calabia ER, Banzo I, Martínez-Rodríguez I, Carril JM (2011) Hepatorenal polycystic disease and fever: diagnostic contribution of gallium citrate Ga 67 scan and fluorine F 18 FDG-PET/CT. Eur Urol 59:297–299
Soussan M, Sberro R, Wartski M, Fakhouri F, Pecking AP, Alberini JL (2008) Diagnosis and localization of renal cyst infection by 18F-fluorodeoxyglucose PET/CT in polycystic kidney disease. Ann Nucl Med 22:529–531
Bleeker-Rovers CP, de Sévaux RG, van Hamersvelt HW, Corstens FH, Oyen WJ (2003) Diagnosis of renal and hepatic cyst infections by 18-F-fluorodeoxyglucose positron emission tomography in autosomal dominant polycystic kidney disease. Am J Kidney Dis 41:E18–E21
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
About this article
Cite this article
Pijl, J.P., Kwee, T.C., Slart, R.H.J.A. et al. FDG-PET/CT for diagnosis of cyst infection in autosomal dominant polycystic kidney disease. Clin Transl Imaging 6, 61–67 (2018). https://doi.org/10.1007/s40336-017-0261-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40336-017-0261-8